Cronos Group Inc. (TSX:CRON) Is the Weed Stock That Grew 95% This Year: This Is Why You Should Avoid it

Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) is performing relatively well, but analysts are apprehensive about the near future. The stock seems to be overvalued, as the market cap is incommensurate with the production capacity.

| More on:
woman data analyze

Image source: Getty Images.

Weed companies continue to claim first-mover advantage to lure investors. But no one can actually tell which one has the decided edge. After the collective decline of cannabis stocks in the last quarter of 2018, investors are avoiding repetition.

Cronos Group (TSX:CRON)(NASDAQ:CRON) appears to be the top performer and holds the upper hand. The stock has risen already by 95% from the year-end price of $14.38. But despite the strong performance thus far, some market analysts believe Cronos is overvalued. It means the stock price could fall any time soon.

The deal buster

Cronos just gained financial muscle after receiving $2.4 billion from Altria Group as part of an investment arrangement. The tobacco giant now owns 45% of Cronos with the option of increasing its stake to 55%. However, investors are far from impressed. Instead of a brighter prognosis, they see a dimmer scenario.

The treasure chest might be overflowing with cash but the production basin is half-empty. This is the expressed concern of many. Production capacity is the key factor to gain substantial market share. Cronos’s current market cap is $5.17 billion, and the company is poised to produce a maximum of 120,000 kilograms annually.

On the contrary, rival Hexo is expected to yield 113,000 kilograms annually at best, but its market cap is only about $1.8 billion. A deal buster right now is Cronos’s tail-end position in the race for production capacity build-up or expansion.

International expansion

Cronos’s cash position vastly improved with Altria’s equity investment. The company has only the markets in Australia and Israel to boast. The bigger market is in Europe, and Cronos needs to make inroads in medical cannabis to gain entry into recreational cannabis.

There’s plenty of work to be done. With Altria’s presence, the chances of penetrating the global cannabis market are higher now. Prior to the team-up with Altria, Cronos sealed a deal with Ginkgo Bioworks; they aim to develop genetically engineered yeast strains to bring forth high-quality cannabinoids.

Both partnerships will determine the success of Cronos moving forward. If the work with Gingko could produce commercial volumes of cannabinoids, then scaling won’t be a problem. Altria needs to be at the forefront of marketing efforts to lock in more deals, especially in Europe. The illusions need to convert to reality.

Cronos made key changes at the senior level to further strengthen the management team. Jerry Barbato, former senior director of corporate strategy at Altria, will be the new CFO, while current CFO William Hilson would serve as the chief commercial officer. The appointments will be effective on April 15.

Less talk, more results

Most of what investors see from Cronos are pipe dreams. The period of talking is over. Investors don’t want to hear talk about leading the cannabis industry forward. Tangible results are needed to earn the trust of investors. At this stage, the situation is “enter at your own risk.”

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »